LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

Search

Bluebird Bio Inc

Closed

0.89 4.71

Overview

Share price change

24h

Current

Min

0.84

Max

0.88

Key metrics

By Trading Economics

Income

1.2M

-72M

Sales

5.5M

12M

EPS

-0.66

Profit margin

-578.849

EBITDA

670K

-84M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+423.33 upside

Dividends

By Dow Jones

Next Earnings

6 sie 2024

Market Stats

By TradingEconomics

Market Cap

5.7M

240M

Previous open

-3.82

Previous close

0.89

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Bluebird Bio Inc Chart

Related News

8 gru 2023, 20:56 UTC

Major Market Movers

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

8 gru 2023, 18:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

8 gru 2023, 16:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

24 lis 2023, 12:00 UTC

Top News

Gene Editing Will Change Medicine -- and Maybe Health Investing Too -- Heard on the Street -- WSJ

Peer Comparison

Price change

Bluebird Bio Inc Forecast

Price Target

By TipRanks

423.33% upside

12 Months Forecast

Average 4.71 USD  423.33%

High 8 USD

Low 1 USD

Based on 9 Wall Street analysts offering 12 month price targets forBluebird Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

4

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

0.845 / 0.9106Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Bluebird Bio Inc

bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.